Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
| 44.54 | |
| 44.7 | |
| - | |
| 45.32 | |
| 43.3 | |
| 9.6-48.7 | |
| 2 702 M | |
| 61 358 K | |
| 79 413 K | |
| 2.222 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
We can readily understand why investors are attracted to unprofitable companies. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring revenu...
It was a regular week for the biotech sector with quite a few important pipeline and regulatory updates. IDEAYA Biosciences IDYA and uniQure N.V. QURE were in the spotlight following positive study da...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
